Most patients undergoing ED cardioversion received guideline-concordant anticoagulation, but dosing variability and follow-up gaps remain, especially in low-risk patients.
While most ED cardioversion patients receive guideline-concordant anticoagulation, variability in post-procedural care and high revisit rates indicate a need for structured follow-up pathways.
Most patients undergoing ED cardioversion received guideline-concordant anticoagulation. However, variability in dosing and post-procedural therapy persists, particularly among low-risk patients. High revisit rates highlight the need for improved follow-up, continuity of anticoagulation, and structured care pathways following ED cardioversion.
Maouris et al. (2026) studied this question. Most patients undergoing ED cardioversion received guideline-concordant anticoagulation, but dosing variability and follow-up gaps remain, especially in low-risk patients.